New HER2-negative breast cancer subtype responsive to anti-HER2 therapy identified

[1] Agus DB(2002)Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth Cancer Cell 2 127-137

[2] Akiyama TSC(1986)The product of the human c-erbB-2 gene: a 185-kilodalton glycoprotein with tyrosine kinase activity Science 232 2733-2743

[3] Ogawara H(2004)Prognostic relevance of gene amplifications and coamplifications in breast cancer Cancer Res 64 8534-8540

[4] Toyoshima K(2012)The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity Nature 483 603-607

[5] Yamamoto T(2012)Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer N Engl J Med 366 109-119

[6] Al-Kuraya K(2014)Quantitative measurements of HER2 and phospho-HER2 expression: correlation with pathologic response to neoadjuvant chemotherapy and trastuzumab BMC Cancer 14 326-645

[7] Barretina J(2006)Phosphorylation of tyrosine 1248-ERBB2 measured by chemiluminescence-linked immunoassay is an independent predictor of poor prognosis in primary breast cancer patients Eur J Cancer 42 636-172

[8] Baselga JCJ(2018)Inhibitor-induced HER2-HER3 heterodimerisation promotes proliferation through a novel dimer interface Elife 7 e32271-98

[9] Kim SB(2014)Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis Lancet 384 164-182

[10] Im SA(2010)Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review J Clin Oncol 28 92-1160

[1] Agus DB(2002)Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth Cancer Cell 2 127-137

[2] Akiyama TSC(1986)The product of the human c-erbB-2 gene: a 185-kilodalton glycoprotein with tyrosine kinase activity Science 232 2733-2743

[3] Ogawara H(2004)Prognostic relevance of gene amplifications and coamplifications in breast cancer Cancer Res 64 8534-8540

[4] Toyoshima K(2012)The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity Nature 483 603-607

[5] Yamamoto T(2012)Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer N Engl J Med 366 109-119

[6] Al-Kuraya K(2014)Quantitative measurements of HER2 and phospho-HER2 expression: correlation with pathologic response to neoadjuvant chemotherapy and trastuzumab BMC Cancer 14 326-645

[7] Barretina J(2006)Phosphorylation of tyrosine 1248-ERBB2 measured by chemiluminescence-linked immunoassay is an independent predictor of poor prognosis in primary breast cancer patients Eur J Cancer 42 636-172

[8] Baselga JCJ(2018)Inhibitor-induced HER2-HER3 heterodimerisation promotes proliferation through a novel dimer interface Elife 7 e32271-98

[9] Kim SB(2014)Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis Lancet 384 164-182

[10] Im SA(2010)Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review J Clin Oncol 28 92-1160